Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study

BACKGROUND AND AIM: Infliximab is typically given over an infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared with the standard 2-hour...

Descripción completa

Detalles Bibliográficos
Autores principales: Abushamma, Suha, Walker, Ted, Garza, Kevin, Chen, Ling, Nix, Darren, Chen, Chien-Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243871/
https://www.ncbi.nlm.nih.gov/pubmed/37288326
http://dx.doi.org/10.1093/crocol/otad022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243871/
https://www.ncbi.nlm.nih.gov/pubmed/37288326
http://dx.doi.org/10.1093/crocol/otad022

Ejemplares similares